Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review

Alberto J. Montero, Betsy Adams, C. Marcela Diaz-Montero, Stefan Glück

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.

Original languageEnglish (US)
Pages (from-to)329-334
Number of pages6
JournalExpert review of clinical pharmacology
Issue number3
StatePublished - May 2011
Externally publishedYes


  • metastatic breast cancer
  • nab-paclitaxel
  • taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review'. Together they form a unique fingerprint.

Cite this